• Shanghai Industrial Investment Holdings’ portfolio companies presented biotechnology updates during a Nov. 7, 2026, visit by Shanghai science officials to SIIC Capital.
• Baiao Jihe outlined AI-native biotechnology progress; Kelaipu covered integrated mass spectrometry applications; Pengpai Xinyao reviewed consumer-focused innovative drug commercialization.
• The Shanghai Biopharmaceutical Fund operates nine funds covering domestic and overseas investments across all stages, totaling approximately 18 billion yuan.
• Its portfolio comprises 71 companies, with two-thirds focused on innovative drugs.
• The group plans closer coordination with Shanghai’s science commission through SIIC Capital and the fund to support biopharmaceutical innovation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Industrial Investment Holdings Co Ltd published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.